menu
    • menu
    [{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Capital Grand Est","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"ODI-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Odimma Therapeutics \/ Capital Grand Est","highestDevelopmentStatusID":"4","companyTruncated":"Odimma Therapeutics \/ Capital Grand Est"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"ABL Europe","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"ODI-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Odimma Therapeutics \/ ABL Europe","highestDevelopmentStatusID":"4","companyTruncated":"Odimma Therapeutics \/ ABL Europe"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odimma Therapeutics \/ Odimma Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Odimma Therapeutics \/ Odimma Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Odimma Therapeutics

    Menu

    Odimma Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Odimma Therapeutics

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Odimma Therapeutics

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ODI-2001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Capital Grand Est

                            Deal Size : $2.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Odimma Therapeutics Secures €2 Million to Complete the Preparation of Its First-in-Man Clinical Trial

                            Details : The financing will secure the preparation on Odimma's First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 02, 2023

                            Lead Product(s) : ODI-2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Capital Grand Est

                            Deal Size : $2.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Odimma Therapeutics

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Odimma Therapeutics

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Touchlight

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer ...

                            Details : Odimma will gain access to Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology, providing them with a clinical supply of personalised dbDNA™, to support and underpin the development of their candidate immunotherapy cancer treatment.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Touchlight

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Odimma Therapeutics

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Odimma Therapeutics

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ODI-2001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : ABL Europe

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ABL and Odimma Therapeutics Enter Development Agreement

                            Details : ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing persona...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 17, 2022

                            Lead Product(s) : ODI-2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : ABL Europe

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth